Hit-to-Lead Capabilities
WuXi Biology provides services for hit identification and hit-to-lead programs. We undertake assay development in major target classes, such as GPCRs and transporters, kinases, and ion channels.
Our screening capabilities span from cell line generation to biochemical and cell-based functional assays.
Screening Platform to support Medicinal Chemistry
Major Target Classes
- Enzyme
- Immuno-oncology Checkpoint enzyme
- GPCR
- Nuclear Hormone Receptor
- Transporter
- Ion Channel
- Protein-protein Interaction
- Infectious disease targets
Major Assay platforms
- Fluorescence: FI, FP, HTRF, FRET, FLIPR
- Luminescence (e.g. luciferase, b-lactamase, deGFP, reporter gene)
- Absorbance
- HCS
- Radiometric assays (e.g. SPA, MicroBeta, Filtration)
- LC/MS
- Label free technology
- MSD, Luminex, ELISA
Major Phenotypic Assays
- Proliferation/Anti-proliferation
- Viability/Cytotoxicity
- Apoptosis
- Translocation
- Internalization/Recycling
- Cytokine Profiling
- Cellular Uptake
In Vitro Toxicity Studies
In response to the growing need for early-stage in vitro toxicity testing, WuXi Biology provides a suite of toxicity assays at the cellular level. Using advanced technologies like conventional and automated patch-clamp and high content screening (HCS), these assays can be applied to your lead ID and optimization strategy. The result is a comprehensive analysis of toxicity severity and specificity, guiding candidate compounds through the planning and execution of downstream in vivo tests
New Modalities
WuXi Biology provides customized solutions that enable our partners to achieve success in drug discovery for challenging targets.
